We provide you with 20 years of free, institutional-grade data for MIRM stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of MIRM. Explore the full financial landscape of MIRM stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$7,746,168
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| BJERKHOLT ERIC | Sale | -5,000 | $121.67 | $608,350 | 2026-07-08 |
| Peetz Christopher | Sale | -20,000 | $121.65 | $2,433,000 | 2026-07-08 |
| Peetz Christopher | Derivatives Exercise | 20,000 | 2026-07-08 | ||
| Howe Jolanda | Sale | -2,721 | $120 | $326,520 | 2026-07-02 |
| Howe Jolanda | Sale | -2,594 | $101.95 | $264,458 | 2026-06-18 |
| BJERKHOLT ERIC | Derivatives Exercise | 2,393 | 2026-06-09 | ||
| BJERKHOLT ERIC | Sale | -5,000 | $92.84 | $464,200 | 2026-06-09 |
| Radovich Peter | Derivatives Exercise | 16,988 | 2026-06-08 | ||
| Walbert Timothy P | Derivatives Exercise | 3,977 | 2026-06-02 | ||
| Cardon Lon | Derivatives Exercise | 3,977 | 2026-06-02 | ||
| Ramasastry Saira | Sale | -3,977 | $100 | $397,700 | 2026-06-02 |
| Ramasastry Saira | Derivatives Exercise | 3,977 | 2026-06-02 | ||
| Fischer Laurent | Derivatives Exercise | 3,977 | 2026-06-02 | ||
| Peetz Christopher | Sale | -30,000 | $94.64 | $2,839,200 | 2026-06-02 |
| Peetz Christopher | Derivatives Exercise | 30,000 | 2026-06-02 | ||
| Ramasastry Saira | Sale | -2,000 | $109.47 | $218,940 | 2026-05-18 |
| Ramasastry Saira | Derivatives Exercise | 2,000 | 2026-05-18 | ||
| Ramasastry Saira | Sale | -2,000 | $96.9 | $193,800 | 2026-04-16 |
| Ramasastry Saira | Derivatives Exercise | 2,000 | 2026-04-16 | ||
| BJERKHOLT ERIC | Sale | -7,287 | $91.98 | $670,243 | 2026-03-17 |
| BJERKHOLT ERIC | Derivatives Exercise | 13,334 | 2026-03-17 | ||
| Quan Joanne | Sale | -7,287 | $91.98 | $670,243 | 2026-03-17 |
| Quan Joanne | Derivatives Exercise | 13,334 | 2026-03-17 | ||
| Ramasastry Saira | Sale | -2,000 | $90.76 | $181,520 | 2026-03-17 |
| Ramasastry Saira | Derivatives Exercise | 2,000 | 2026-03-17 | ||
| Radovich Peter | Sale | -16,515 | $91.98 | $1,519,015 | 2026-03-17 |
| Radovich Peter | Derivatives Exercise | 30,220 | 2026-03-17 | ||
| Howe Jolanda | Sale | -4,732 | $91.98 | $435,239 | 2026-03-17 |
| Howe Jolanda | Derivatives Exercise | 8,658 | 2026-03-17 | ||
| Peetz Christopher | Sale | -40,985 | $91.98 | $3,769,714 | 2026-03-17 |
| Peetz Christopher | Derivatives Exercise | 75,000 | 2026-03-17 | ||
| Radovich Peter | Derivatives Exercise | 5,912 | 2026-03-11 | ||
| Ramasastry Saira | Sale | -2,000 | $102.09 | $204,180 | 2026-02-17 |
| Ramasastry Saira | Derivatives Exercise | 2,000 | 2026-02-17 | ||
| Peetz Christopher | Sale | -9,108 | $103.3 | $940,888 | 2026-02-03 |
| Howe Jolanda | Sale | -968 | $103.3 | $99,998 | 2026-02-03 |
| Howe Jolanda | Derivatives Exercise | 1,771 | 2026-02-03 |
The information provided in this report about MIRM stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Mirum Pharmaceuticals, Inc(NASDAQ:MIRM) 
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial ...
Website: http://www.mirumpharma.com
Founded: 2018
Full Time Employees: 67
CEO: Christopher Peetz
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends